Cancer is currently the second leading cause of death globally and is expected to be
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …

With the advent of targeted agents for the treatment of renal cell carcinoma (RCC), overall
survival has improved, and patients are being treated continuously for increasingly long …

Purpose To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in
patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational …

Context In a randomized phase 3 trial, 400 mg of sorafenib twice daily prolonged overall
survival of patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh A …

Importance Previous communication has reported significant improvement in overall survival
(OS) when using doxorubicin plus sorafenib in the treatment of advanced hepatocellular …

Highlights•This ESMO Clinical Practice Guideline provides recommendations on the
prevention/management of dermatological toxicities.•Authorship includes a multidisciplinary …

The effect of blocking VEGF activity in solid tumors extends beyond inhibition of
angiogenesis. However, no studies have compared the effectiveness of mechanistically …

Background The multitargeted kinase inhibitors sorafenib and sunitinib have improved
treatment of solid tumours including renal cell carcinoma and hepatocellular carcinoma by …

Targeted drugs are increasingly being used for cancer management. They are designed to
block specific cancer cell processes, and are often better tolerated than conventional …

Abstract Hand-foot syndrome (HFS), also called hand-foot skin reaction, palmar-plantar
erythrodysesthesia, acral erythema, and Burgdorf reaction, is a dose-limiting cutaneous …